Corcept Therapeutics (CORT) Expected to Announce Earnings on Monday

Corcept Therapeutics (NASDAQ:CORT - Get Free Report) is anticipated to announce its Q1 2025 earnings results after the market closes on Monday, May 5th. Analysts expect the company to announce earnings of $0.17 per share and revenue of $177.93 million for the quarter. Corcept Therapeutics has set its FY 2025 guidance at EPS.

Corcept Therapeutics (NASDAQ:CORT - Get Free Report) last posted its earnings results on Wednesday, February 26th. The biotechnology company reported $0.26 earnings per share for the quarter, missing analysts' consensus estimates of $0.37 by ($0.11). Corcept Therapeutics had a return on equity of 24.54% and a net margin of 22.35%. The firm had revenue of $181.89 million for the quarter, compared to analyst estimates of $200.12 million. On average, analysts expect Corcept Therapeutics to post $1 EPS for the current fiscal year and $2 EPS for the next fiscal year.

Corcept Therapeutics Stock Performance

Shares of CORT stock traded up $1.29 on Friday, hitting $72.77. The company's stock had a trading volume of 1,231,617 shares, compared to its average volume of 1,118,568. Corcept Therapeutics has a fifty-two week low of $23.02 and a fifty-two week high of $117.33. The company has a market capitalization of $7.72 billion, a PE ratio of 57.75 and a beta of 0.22. The stock's 50 day moving average is $65.70 and its 200-day moving average is $59.99. The company has a debt-to-equity ratio of 0.01, a quick ratio of 3.64 and a current ratio of 3.70.

Wall Street Analyst Weigh In

CORT has been the topic of a number of analyst reports. Canaccord Genuity Group increased their target price on shares of Corcept Therapeutics from $130.00 to $142.00 and gave the stock a "buy" rating in a research report on Tuesday, April 1st. Piper Sandler lifted their price objective on Corcept Therapeutics from $128.00 to $131.00 and gave the company an "overweight" rating in a report on Thursday, April 3rd. Truist Financial upped their target price on Corcept Therapeutics from $76.00 to $150.00 and gave the company a "buy" rating in a research report on Monday, March 31st. HC Wainwright raised their price target on Corcept Therapeutics from $115.00 to $150.00 and gave the stock a "buy" rating in a research report on Monday, March 31st. Finally, StockNews.com cut shares of Corcept Therapeutics from a "buy" rating to a "hold" rating in a research report on Friday, February 28th. One research analyst has rated the stock with a hold rating and five have given a buy rating to the company. Based on data from MarketBeat, Corcept Therapeutics has an average rating of "Moderate Buy" and an average price target of $143.25.

Insider Buying and Selling at Corcept Therapeutics

In related news, insider Sean Maduck sold 100,000 shares of the stock in a transaction that occurred on Monday, March 31st. The shares were sold at an average price of $100.54, for a total value of $10,054,000.00. Following the completion of the transaction, the insider now owns 85,622 shares of the company's stock, valued at $8,608,435.88. This represents a 53.87 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Daniel N. Swisher, Jr. sold 2,200 shares of the business's stock in a transaction on Monday, February 10th. The stock was sold at an average price of $68.08, for a total transaction of $149,776.00. The disclosure for this sale can be found here. In the last quarter, insiders have sold 163,124 shares of company stock valued at $15,117,614. 20.50% of the stock is currently owned by corporate insiders.

About Corcept Therapeutics

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery.